Combination Cancer Immunotherapy

Our scientists are developing technology that combines anti-cancer therapies, including immunotherapy, in a single agent to directly target cancer tumors. This type of agent is capable of greater potency, higher specificity, and less toxicity than the many therapies that can also attack healthy cells.

The thrust of our current efforts is to combine our agents with other immunotherapeutics, such as checkpoint inhibitors, to achieve greater overall response rates and durable responses in patients than are currently observed in the clinic.

CEOCFO Magazine

Advanced Proteome Therapeutics Corp is focused on developing a Protein Therapeutic that is Targeted and Combines Anti-Cancer Therapies for Greater Potency, Higher Specificity and Less Toxicity than Individual Therapies.

Latest

April 13, 2015

Advanced Proteome Therapeutics announces new patent

View PDF

April 7, 2015

Advanced Proteome Therapeutics announces promising results of triple combination immunotherapy tests

View PDF

March 30, 2015

Advanced Proteome Therapeutics appoints Dr. David Webb to its Corporate Advisory Board

View PDF

March 23, 2015

Advanced Proteome Therapeutics provides corporate update on multiple activities.

View PDF
Video

Targeted Cancer Therapeutics and Immunotherapy

A 4 minute video interview with Dr. Allen Krantz and a visit to the company's lab.

Play Video
Video

In-Depth Version - Targeted Cancer Therapeutics and Immunotherapy

A 10 minute video interview with Dr. Allen Krantz and a visit to the company's lab.

Play Video
Disclaimer

This website contains historical and forward-looking statements. The forward-looking statements involve risks and uncertainties. Forward looking statements appearing on this website in this presentation represent management's current estimates at the time they were posted and these may change significantly as new information comes to hand. The information contained in this website has been obtained by Advanced Proteome Therapeutics Corporation. from its own records and from other sources believed to be reliable, however no representation or warranty is made as to its accuracy or completeness. Reference should be made to the Company's most recent Annual Report filed with Canadian securities regulatory authorities (and available at www.sedar.com) for a description of the major risk factors.

Advanced Proteome Therapeutics Corporation.

Suite 113
650 Albany Street
Boston, Massachusetts
02118 USA

T 617-638-0340
F 617-638-0341
www.advancedproteome.com
akrantz@advancedproteome.com